Intraoperative molecular analysis of sentinel lymph nodes following neoadjuvant chemotherapy in patients with clinical node negative breast cancer: An institutional study

Sentinel lymph node biopsy (SLNB) is an accurate, safe method for determining the axillary lymph node status. However, insufficient evidence exists to support the recommendation of SLNB in patients who have had neoadjuvant chemotherapy (NAC) to downsize tumours and allow for breast conservation surg...

Descripción completa

Detalles Bibliográficos
Autores principales: Parada, David, Peña, Karla B., Riu, F. Francesc, Aguilar, A. Esther, Cohan, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5103850/
https://www.ncbi.nlm.nih.gov/pubmed/27882235
http://dx.doi.org/10.3892/mco.2016.1025
_version_ 1782466655336529920
author Parada, David
Peña, Karla B.
Riu, F. Francesc
Aguilar, A. Esther
Cohan, Sebastian
author_facet Parada, David
Peña, Karla B.
Riu, F. Francesc
Aguilar, A. Esther
Cohan, Sebastian
author_sort Parada, David
collection PubMed
description Sentinel lymph node biopsy (SLNB) is an accurate, safe method for determining the axillary lymph node status. However, insufficient evidence exists to support the recommendation of SLNB in patients who have had neoadjuvant chemotherapy (NAC) to downsize tumours and allow for breast conservation surgery. The present study aimed to use molecular approaches to evaluate the feasibility and accuracy of SLNB in patients treated with NAC prior to SLN mapping and surgery. A total of 50 consecutive patients with operable invasive breast carcinomas who had received prior NAC were assessed using the one-step nucleic acid amplification (OSNA) method. The rate of SLN identification was 100%. The OSNA assay showed that 29 patients (58%) were negative for SLN and 21 patients (42%) were positive. In 19 of these 21 patients (90.48%), the SLN was the only positive lymph node. No axillary lymph nodes metastases were observed in patients with isolated tumour cells or with micrometastases. The OSNA assay is a highly sensitive, specific and reproducible diagnostic technique that can be used to analyse SLNs following NAC. The total tumoral load may assist with predicting additional non-SLN metastases.
format Online
Article
Text
id pubmed-5103850
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-51038502016-11-23 Intraoperative molecular analysis of sentinel lymph nodes following neoadjuvant chemotherapy in patients with clinical node negative breast cancer: An institutional study Parada, David Peña, Karla B. Riu, F. Francesc Aguilar, A. Esther Cohan, Sebastian Mol Clin Oncol Articles Sentinel lymph node biopsy (SLNB) is an accurate, safe method for determining the axillary lymph node status. However, insufficient evidence exists to support the recommendation of SLNB in patients who have had neoadjuvant chemotherapy (NAC) to downsize tumours and allow for breast conservation surgery. The present study aimed to use molecular approaches to evaluate the feasibility and accuracy of SLNB in patients treated with NAC prior to SLN mapping and surgery. A total of 50 consecutive patients with operable invasive breast carcinomas who had received prior NAC were assessed using the one-step nucleic acid amplification (OSNA) method. The rate of SLN identification was 100%. The OSNA assay showed that 29 patients (58%) were negative for SLN and 21 patients (42%) were positive. In 19 of these 21 patients (90.48%), the SLN was the only positive lymph node. No axillary lymph nodes metastases were observed in patients with isolated tumour cells or with micrometastases. The OSNA assay is a highly sensitive, specific and reproducible diagnostic technique that can be used to analyse SLNs following NAC. The total tumoral load may assist with predicting additional non-SLN metastases. D.A. Spandidos 2016-11 2016-09-21 /pmc/articles/PMC5103850/ /pubmed/27882235 http://dx.doi.org/10.3892/mco.2016.1025 Text en Copyright: © Parada et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Parada, David
Peña, Karla B.
Riu, F. Francesc
Aguilar, A. Esther
Cohan, Sebastian
Intraoperative molecular analysis of sentinel lymph nodes following neoadjuvant chemotherapy in patients with clinical node negative breast cancer: An institutional study
title Intraoperative molecular analysis of sentinel lymph nodes following neoadjuvant chemotherapy in patients with clinical node negative breast cancer: An institutional study
title_full Intraoperative molecular analysis of sentinel lymph nodes following neoadjuvant chemotherapy in patients with clinical node negative breast cancer: An institutional study
title_fullStr Intraoperative molecular analysis of sentinel lymph nodes following neoadjuvant chemotherapy in patients with clinical node negative breast cancer: An institutional study
title_full_unstemmed Intraoperative molecular analysis of sentinel lymph nodes following neoadjuvant chemotherapy in patients with clinical node negative breast cancer: An institutional study
title_short Intraoperative molecular analysis of sentinel lymph nodes following neoadjuvant chemotherapy in patients with clinical node negative breast cancer: An institutional study
title_sort intraoperative molecular analysis of sentinel lymph nodes following neoadjuvant chemotherapy in patients with clinical node negative breast cancer: an institutional study
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5103850/
https://www.ncbi.nlm.nih.gov/pubmed/27882235
http://dx.doi.org/10.3892/mco.2016.1025
work_keys_str_mv AT paradadavid intraoperativemolecularanalysisofsentinellymphnodesfollowingneoadjuvantchemotherapyinpatientswithclinicalnodenegativebreastcanceraninstitutionalstudy
AT penakarlab intraoperativemolecularanalysisofsentinellymphnodesfollowingneoadjuvantchemotherapyinpatientswithclinicalnodenegativebreastcanceraninstitutionalstudy
AT riuffrancesc intraoperativemolecularanalysisofsentinellymphnodesfollowingneoadjuvantchemotherapyinpatientswithclinicalnodenegativebreastcanceraninstitutionalstudy
AT aguilaraesther intraoperativemolecularanalysisofsentinellymphnodesfollowingneoadjuvantchemotherapyinpatientswithclinicalnodenegativebreastcanceraninstitutionalstudy
AT cohansebastian intraoperativemolecularanalysisofsentinellymphnodesfollowingneoadjuvantchemotherapyinpatientswithclinicalnodenegativebreastcanceraninstitutionalstudy